Herantis Pharma receives Life Sciences Nordic Stars Award
(Thomson Reuters ONE) -
Herantis Pharma receives Life Sciences Nordic Stars Award
Herantis Pharma Plc
Press release 15 Sep 2017 at 8:30 am
Herantis Pharma plc ("Herantis") received the Nordic Stars Award at the Nordic
Life Sciences Days in Malmö, Sweden. Nordic Stars Awards winners have been
selected annually since 2013 "in special recognition of life science companies
in the Nordic region demonstrating outstanding innovation and entrepreneurial
skills." The other winners in 2017 were Targovax (Norway) and Pelago Bioscience
(Sweden).
"This award is above all a recognition of the high quality of scientific
research in Finland", appreciates Pekka Simula, Herantis' CEO. "Our drug
candidate Lymfactin® is based on the scientific research by professor Kari
Alitalo's group, and our drug candidate CDNF is based on the research by
professor Mart Saarma's group. Both are examples of ground-breaking medical
research in Finland representing globally leading science. This recognition also
reminds of the opportunities that high-quality science will open in the future
for Finland, our nation now celebrating 100 years of independence."
Further information:
Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on
regenerative medicine for breakthrough in unmet clinical needs. Our first-in-
class assets are based on globally leading scientific research in their fields:
CDNF for disease modification in neurodegenerative diseases, primarily
Parkinson's and ALS; and Lymfactin® for breast cancer associated lymphedema,
with potential also in other lymphedemas. The shares of Herantis are listed on
the First North Finland marketplace run by Nasdaq Helsinki stock exchange.
About CDNF
CDNF is a novel drug candidate for the treatment of neurodegenerative diseases.
Naturally present in the human blood circulation and cerebrospinal fluid, CDNF
is a protein with neuroprotective and neurorestorative properties, patented
worldwide by Herantis. Encouraged by strong preclinical proof-of-concept
Herantis has launched a first-in-human, randomized Phase 1-2 clinical study with
CDNF for the treatment of Parkinson's disease. The clinical study has received
funding from the European Union's research and innovation program Horizon 2020
under grant agreement number 732386.
CDNF administration has been safe in preclinical studies including chronic
toxicology studies; CDNF has protected and regenerated midbrain dopamine-
generating cells suggesting potential for disease modification of PD. It has
also shown efficacy in non-motor symptoms of PD. In an ALS disease model CDNF
has significantly increased survival and reduced symptoms. This suggests the
potential to address unmet clinical needs in both PD and ALS. CDNF drug
development is based on scientific research at the University of Helsinki, lead
by professor Mart Saarma.
About Lymfactin®
Lymfactin® is the world's first clinical stage gene therapy repairing damages of
the lymphatic system. Lymfactin® expresses the growth factor VEGF-C, which is
specific to the development of lymphatic vessels. Based on preclinical studies
Lymfactin® triggers the growth of new functional lymphatic vasculature and thus
repairs the damages causing secondary lymphedema. Encouraged by preclinical
results Herantis has launched a Phase 1 clinical study with Lymfactin® in the
treatment of breast cancer associated lymphedema. Patented by Herantis,
Lymfactin® is based on scientific research by academy professor Kari Alitalo and
his research group, a national centre of excellence at the University of
Helsinki. See our introductory video on Lymfactin®:
http://herantis.com/media/videos/
Distribution:
Main media
www.herantis.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Golden Dawn Signs Agency Agreement with First Berlin Securities BrokerageDatum: 15.09.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 560050
Anzahl Zeichen: 4813
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 275 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Herantis Pharma receives Life Sciences Nordic Stars Award"
steht unter der journalistisch-redaktionellen Verantwortung von
Herantis Pharma Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
